Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma — Jean‐Luc Harousseau (2010) | RDL Network
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
Continuing treatment with lenalidomide plus dexamethasone to achieve best response, in the absence of disease progression and toxicity, provided deeper remissions and greater clinical benefit over time for patients in this study.
Edward A. Stadtmauer, D. Weber, R. Nieszvizky, Andrew R. Belch, H. Miles Prince, Jesús F. San Miguel, Thierry Façon, Zhinuan Yu, Robert Knight, Meletios A Dimopoulos
Meletios A Dimopoulos, Jesús F. San Miguel, Andrew R. Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Heather J. Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis, Ajai Chari, Lisa O’Rourke, Kaida Wu, Jordan M. Schecter, Tineke Casneuf, Christopher Chiu, David Soong, A. Kate Sasser, Nushmia Z. Khokhar, Hervé Avet‐Loiseau, Saad Z. Usmani
Jesús F. San Miguel, Meletios A Dimopoulos, Edward A. Stadtmauer, S. Vincent Rajkumar, David S. Siegel, Marie‐Laure Casadebaig Bravo, Marta Olesnyckyj, Robert Knight, Jerome B. Zeldis, Jean‐Luc Harousseau, Donna M. Weber
Edward A. Stadtmauer, Donna M. Weber, Rubén Niesvizky, Andrew Belch, Miles H. Prince, Jesús F. San Miguel, Thierry Façon, Marta Olesnyckyj, Zhinuan Yu, Jerome B. Zeldis, Robert Knight, Meletios A Dimopoulos
Michael Wang, Meletios A Dimopoulos, Christine Chen, María Teresa Cibeira, Michel Attal, Andrew Spencer, S. Vincent Rajkumar, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight, Donna M. Weber
Discussion(0)
No comments yet. Be the first to comment.